IBIO
iBio, Inc. (IBIO) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
The company’s current ratio of 7.85 and quick ratio of 7.85 indicate ample near-term liquidity, but peers with stronger operating franchises typically convert that cushion into growth more efficiently.
Debt-to-equity of 0.03 suggests limited balance-sheet leverage, which reduces refinancing pressure versus more indebted peers, yet it does not create a durable competitive advantage.
Net debt to EBITDA of 1.68 appears manageable on a relative basis, but the absence of positive EBITDA limits the strategic value of that leverage profile versus profitable peers.
Weaknesses
Return on invested capital of -39.97% signals severe capital destruction, leaving IBIO structurally behind peers that generate positive returns on deployed capital.
Cash conversion cycle of 4,029.6 days indicates extreme working-capital inefficiency, which is far worse than peers and constrains reinvestment capacity.
The lack of reported operating and gross margins suggests an unproven earnings model, whereas stronger peers typically demonstrate repeatable margin capture.
Low leverage does not offset weak operating performance, because peers with similar balance-sheet flexibility usually pair it with profitable scale and cash generation.
Opportunities
If management shortens the 4,029.6-day cash conversion cycle, capital efficiency could improve materially, though peers already operating near normal cycles would retain an advantage.
A stronger liquidity position could support selective execution or restructuring, but peers with established revenue engines can usually deploy capital more productively.
Any future margin disclosure improvement would help credibility, yet peers with existing positive margins would still set the benchmark for structural positioning.
Threats
Persistent negative ROIC increases the risk that peers with positive returns will compound market share and financing access faster over the next two to five years.
The extraordinary cash conversion cycle heightens dilution and liquidity risk, especially versus peers that recycle cash quickly into operations.
If operating losses continue, the company may remain dependent on external funding while stronger peers self-fund growth and absorb shocks more easily.
Overall Score
IBIO’s structural positioning versus peers is weak because severe capital inefficiency and negative returns outweigh its liquidity and low-leverage profile.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on iBio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
